NCT07062484View on ClinicalTrials.gov

A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

NANot yet recruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Lung Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG

Control: gemcitabine, cisplatin, tirelizumab

PD-1 inhibitors combined with chemotherapy

DRUG

Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy

PD-1 inhibitors combined with chemoradiotherapy

Trial Locations (1)

610041

Sichuan Cancer Hospital and Research Institute, Chengdu

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT07062484 - A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter